METHODS OF INHIBITING INFLAMMATION AND INFLAMMATORY DISEASES USING Gal-3BP (BTBD17B, LGALS3BP, GALECTIN-3 BINDING PROTEIN, MAC-2 BINDING PROTEIN)
AssigneeLa Jolla Institute for Allergy and Immunology
InventorsKlaus Ley, Iftach Shaked
Life of this patent
Estimating the term…
Abstract
The invention provides Galectin-3 binding protein (Gal-3BP, BTBD17B) polypeptides, Gal-3BP compositions, and methods of use, and uses, for example, in treatment, diagnostic, detection and prognostic methods, such as treatment of an undesirable or aberrant immune response, immune disorder, inflammatory response, or inflammation, and treatment of an autoimmune response, disorder or disease.
Claims31
A method of decreasing, reducing, inhibiting, suppressing, limiting or controlling an undesirable or aberrant immune response, immune disorder, inflammatory response, inflammation or an autoimmune response, disorder or disease in a subject, comprising administering a Galectin-3 binding protein (Gal-3BP, BTBD17B) polypeptide or fragment thereof to a subject in an amount to decrease, reduce, inhibit, suppress, limit or control the undesirable or aberrant immune response, immune disorder, inflammatory response, inflammation or autoimmune response, disorder or disease in the subject, wherein the subject has not been diagnosed for an adverse cardiovascular event or cardiovascular disease.
(canceled)
-6. (canceled)
The method of claim 5, wherein the NFAT activation is indicated by stimulated, promoted, increased or induced macrophage microRNA expression, has-miR-21, has-miR-23b, has-miR-24, has-miR-27a or has-miR-125a-5p.
-13. (canceled)
(canceled)
-18. (canceled)
(canceled)
The method of claim 12, wherein the Galectin-3 binding protein (Gal-3BP, BTBD17B) polypeptide subsequence is residues 24-124 (SRCR domain);
- residues 153-221 (BTB domain);
- or residues 260-360 (BACK domain).
-33. (canceled)
-37. (canceled)
(canceled)
(canceled)
A pharmaceutical composition comprising Galectin-3 binding protein (Gal-BP, BTBD17B) and an anti-inflammatory drug or agent.
A method of stimulating, promoting, increasing or inducing interleukin-2 (IL-2) production by or secretion from macrophages or dendritic cells or decreasing, reducing or inhibiting TNF-alpha or IL-6 production or secretion by splenocytes or macrophages, comprising administering Galectin-3 binding protein (Gal-3BP, BTBD17B) polypeptide or fragment thereof to a subject in an amount that stimulates, promotes, increases or induces interleukin-2 (IL-2) production by or secretion from macrophages or dendritic cells or decreases, reduces or inhibits TNF-alpha or IL-6 production or secretion by splenocytes or macrophages, wherein the subject has not been diagnosed for an adverse cardiovascular event or cardiovascular disease.
A method of decreasing, reducing or inhibiting TNF-alpha or IL-6 production or secretion by splenocytes or macrophages, comprising administering Galectin-3 binding protein (Gal-3BP, BTBD17B) polypeptide or fragment thereof to a subject in an amount that decreases, reduces or inhibits TNF-alpha or IL-6 production or secretion by splenocytes or macrophages, wherein the subject has not been diagnosed for an adverse cardiovascular event or cardiovascular disease.
Dependencies are inferred from the claim text.